

HeraCARE PRO successfully integrated into Hapvida's hospital systems

- HeraBEAT device and HeraCARE PRO SaaS platform integrated into Hapvida's Electronic Medical Record systems - first commercial integration provides product validation
- Hapvida services over 6.5 million customers through their network of circa 100 hospitals and 1,000 clinics across 11 Brazilian states
- Integration included rigorous technical testing enabling medical professionals to use HeraBEAT as an alternative to competitors' monitoring devices at the hospital (Cost US\$5,000-10,000 per unit)
- Platform evaluated by Hapvida's medical team with its accuracy, reliability and effectiveness are now validated and approved
- Integration included seamless data upload and sharing between HeraBEAT and customised HeraCARE PRO platform
- HeraCARE PRO now supports immediate data upload from HeraBEAT via the cloud to Hapvida's infrastructure enabling the medical team to view analytics in real-time
- 100 HeraBEAT devices now being distributed across Hapvida's network for broader testing across multiple hospitals
- Trial valued at US\$60,000 which includes 100 devices and 2400 subscription licences (100 users calculated per device per month for 24 months) - as announced previously (ASX announcement: 14 February 2019)
- Pricing structure optimised in the future with HeraCARE to be valued at US\$69-\$99 per month per user (5 months use expected on average)
- Brazil has over 2.9 million new births per year

Medical technology company, **HeraMED Limited (ASX:HMD)** ("HeraMED" or the "Company") is pleased to provide an update on its pilot trial with one of Brazil's largest healthcare providers Hapvida Saude (Hapvida), for the Company's HeraBEAT smart medical grade foetal HR Monitor and its cloud based software as a service (SaaS) pregnancy monitoring software, HeraCARE (ASX announcement: 14 February 2019).

HeraMED is pleased to advise that the Company has successfully integrated its HeraCARE software offering into Hapvida's IT systems, which will allow physicians and nurses to monitor real time patient data generated from HeraMED's smart foetal heart rate monitor, the HeraBEAT device.

The integration took place over a four month period in which both HeraBEAT and HeraCARE PRO were stringently tested and reviewed by Hapvida's medical professionals. During this period, both the device and platform were tested in a number of challenging hospital scenarios, as well as challenging cellular connectivity. HeraMED is pleased to advise that the offering passed all of these tests.

This integration of HeraCARE is a significant milestone for the Company, as it marks the first time the solution has been implemented into Hospitals IT systems. The implementation of HeraMED's software with Hapvida provides considerable validation of the Company's software offering and its ability to scale well ahead of schedule.

Hapvida services over 6.5 million customers nationwide through a network of circa 100 hospitals, 1,000 clinics, across 11 states. It is one of Brazil's largest healthcare providers and medical insurance companies.

Now that the first step of full technical integration has been completed, HeraMED will begin a more extensive pilot trial with the group. HeraBEAT devices are now being distributed across Hapvida's network, which will be used in place of professional monitors which cost upwards of US\$10,000 which do not offer data collection and external monitoring capabilities via the HeraCARE PRO platform (outlined Figure 1 below).

Following ongoing feedback from the medical community, HeraMED has considerably progressed the development of HeraCARE into a broader homecare oriented "HeraCARE home". The Company will add additional features and an alternative pricing structure, which can be potentially rolled out through Insurance companies, hospital networks and medical organisations. HeraMED will update shareholders on this progress in the coming weeks.

HeraMED CEO and Co-founder Mr David Groberman said: "The inaugural integration of HeraCARE into an external Hospital IT system is a tremendous milestone for HeraMED as it provides validation of our service offering and its potential with large medical organisations across the globe.

"The pilot trial with Hapvida will utilise both the customised HeraCARE PRO and HeraBEAT to provide a cheaper, more accurate and full service offering to medical personnel, as well as lay a strong foundation for growth and product development.

"Following feedback from Hapvida and other medical organisations in the Company's network, HeraMED is also progressing the development of a more advanced service offering under the HeraCARE banner. Development is underway and we look forward to updating shareholders on this offering in the near term."



Measurement Summary

Details	
Patient Name:	Jane Doe
Pregnancy Week:	24
Measurement Number:	1
Measurement Date:	26 Jun 2019
Measurement Start:	15:43
Measurement End:	16:08

Highlights	
Total Measurement Duration:	25:07 Min
Total Search Duration:	00:06 Min
Total Recorded FHR:	25:01 Min
Longest Continuous FHR Segment:	25:01 Min
Number of FHR Segments:	1
- Avg FHR:	144 BPM
- Avg MHR:	89 BPM




Figure 1:

-ENDS-

HeraMED Limited
 CEO and Co-Founder
 David Groberman
 M: +972-52-6991188
 E: David@hera-med.com

Company Secretary
 Stephen Buckley
 T: +61 (0)8 6189 1155
 E: stephen@companysecsol.com.au

Released through: Henry Jordan, Six Degrees Investor Relations, +61 431 271 538

About HeraMED Limited (ASX:HMD):

HeraMED Limited is an innovative medical technology company delivering smart pregnancy monitoring solutions for home and professional use. HeraMED provides peace of mind to expecting parents by solving challenges associated with the reliability and accessibility of pre-natal care. Through development and utilisation of end-to-end medical grade solutions, HeraMED overcomes the barriers of high-cost and shortage of fundamental services, enabling smart monitoring devices, cloud-based platform and AI capabilities

HeraMED is commercialising its smart medical grade ultrasound monitoring device, HeraBEAT. The device has passed multiple clinical trials and secured approval by key regulatory bodies including TGA (Australia), CE (Europe) and AMAR (Israel) for commercial sale.

The Company has partnerships with two leading medical organisations, the Mayo Clinic and TEVA Pharmaceutical Industries Inc. (NYSE: TEVA). HeraMED diversifying its product range and services with the launch of SaaS services and cloud based monitoring systems.